The efficacy endpoint for the trial is deep response rate, defined as CR plus PRs of greater than 50% tumor volume reduction ... induction of antibody production from B cells and effects on lymphocyte ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback